Thomas Powles

机构：Twitter (United States), National Health Service, St Bartholomew's Hospital, Queen Mary University of London, Royal Free London NHS Foundation Trust, Barts Health NHS Trust, The Royal Free Hospital, Cancer Research UK, University College London

发表论文 385 篇 · 总被引 36632 次 · h-index 71

代表论文

• Nivolumab plus ipilimumab vs sunitinib for first-line treatment of advanced renal cell carcinoma: Final analysis from the phase 3 CheckMate 214 trial. (2025 · Journal of Clinical Oncology · 被引 20)
• Exploratory subgroup analyses of EV-302: a phase III global study to evaluate enfortumab vedotin in combination with pembrolizumab versus chemotherapy in previously untreated locally advanced or metastatic urothelial carcinoma (2025 · ESMO Open · 被引 17)
• Cabozantinib (C) in combination with nivolumab (N) and ipilimumab (I) in previously untreated advanced renal cell carcinoma (aRCC): Final results of COSMIC-313. (2025 · Journal of Clinical Oncology · 被引 13)
• Assessing pathological response to neoadjuvant therapy in renal cell carcinoma: a systematic review and guidelines for sampling and reporting standards from the International Neoadjuvant Kidney Cancer Consortium (2025 · The Lancet Oncology · 被引 9)
• Established and emerging biomarkers approaches in urothelial carcinoma (2025 · Expert Review of Anticancer Therapy · 被引 7)
• Avelumab First-line Maintenance for Advanced Urothelial Carcinoma: Long-term Outcomes from the JAVELIN Bladder 100 Trial in Patients with Nonvisceral or Lymph Node–only Disease (2025 · European Urology · 被引 7)